RCDTF (RCDTF) Stock Price & Analysis
RCDTF (RCDTF) rose 0.00% to USD 60 as of June 9, 2026 at 23:52 UTC, according to Nexqual real-time market data.
RCDTF last closed at USD 60; the session ranged USD 60–60 on volume of 100 shares. Market capitalization is $12.21B, with a 52-week range of USD 55.88–65.44 (PNK). Source: Nexqual, June 9, 2026 at 23:52 UTC.
Key Statistics (as of June 9, 2026 at 23:52 UTC)
| Price | USD 60 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 60 |
| Open | USD 60 |
| Day Range | USD 60 – 60 |
| 52-Week Range | USD 55.88 – 65.44 |
| Volume | 100 shares |
| Market Cap | $12.21B |
| Exchange | PNK |
Technical Analysis (RCDTF)
Nexqual's technical model rates RCDTF "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:52 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 87.7 (overbought) |
| vs SMA50 | Above (USD 57.25) |
| MACD | 0.97 (positive) |
Analyst Ratings (RCDTF)
Wall Street analysts rate RCDTF "None", per Nexqual as of June 9, 2026 at 23:52 UTC.
| Consensus Rating | None |
|---|
Earnings (RCDTF)
| Next Earnings Date | 2026-07-28 |
|---|
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Financials & Fundamentals (RCDTF)
| Total Revenue | $2.65B |
|---|---|
| Revenue Growth (YoY) | +4.90% |
| Gross Margin | +71.05% |
| Operating Margin | +32.38% |
| Profit Margin | +17.79% |
| ROE | +23.36% |
| Debt / Equity | 115.13 |
| Current Ratio | 1.26 |
| Total Cash | $380.47M |
| Total Debt | $2.37B |
| Free Cash Flow | $536.78M |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Financial Health Score (RCDTF)
Nexqual rates RCDTF's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:52 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 32% |
| Balance Sheet | Mixed — $380M cash vs $2.37B debt |
| Cash Flow | Strong — FCF $537M, 21% margin |
| Efficiency | Strong — ROE 23%, ROA 9.5% |
Ownership (RCDTF)
| Insider Ownership | +46.80% |
|---|---|
| Institutional Ownership | +32.06% |
| Shares Outstanding | 203.46M |
| Float | 107.50M |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Leadership (RCDTF)
RCDTF is led by Robert Koremans (age 63), CEO & Director, per Nexqual as of June 9, 2026 at 23:52 UTC.
| CEO & Director | Robert Koremans (age 63) |
|---|---|
| Executive Director | Cathrin Petty (age 52) |
| Executive Director | Giampiero Mazza (age 56) |
| Chief Financial Officer | Michael McClellan (age 54) |
| Group Communications Director | Laura Conti |
Major Backers & Investors (RCDTF)
Notable institutional backers of RCDTF include Fidelity, AIM Intl Mutual Fd.s -Invesco Intl Small-Mid Company Fd., according to Nexqual as of June 9, 2026 at 23:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 2.88% |
| AIM Intl Mutual Fd.s -Invesco Intl Small-Mid Company Fd. | 0.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.25% |
| BlackRock | 0.39% |
Source: Nexqual, June 9, 2026 at 23:52 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IPSEY | Ipsen S.A. | USD 42.27 | ▼ 6.15% |
| HKMPF | Hikma Pharmaceuticals plc. | USD 19.07 | ▼ 1.14% |
| DSRLF | DIASORIN SPA | USD 84.1 | ▲ 0% |
| UCBJF | UCB S.A. | USD 290 | ▼ 7.56% |
| ORINY | Orion Corporation OY | USD 40.63 | ▲ 6.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:52 UTC. This page is informational and not investment advice.